147 related articles for article (PubMed ID: 15807874)
21. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors.
Strosberg JR; Cheema A; Weber J; Han G; Coppola D; Kvols LK
J Clin Oncol; 2011 Aug; 29(22):3044-9. PubMed ID: 21709192
[TBL] [Abstract][Full Text] [Related]
22. Stage IV Gastro-Entero-Pancreatic Neuroendocrine Neoplasms: A Risk Score to Predict Clinical Outcome.
Panzuto F; Merola E; Pavel ME; Rinke A; Kump P; Partelli S; Rinzivillo M; Rodriguez-Laval V; Pape UF; Lipp R; Gress T; Wiedenmann B; Falconi M; Delle Fave G
Oncologist; 2017 Apr; 22(4):409-415. PubMed ID: 28232598
[TBL] [Abstract][Full Text] [Related]
23. Identification of primary tumors in patients presenting with metastatic gastroenteropancreatic neuroendocrine tumors.
Keck KJ; Maxwell JE; Menda Y; Bellizzi A; Dillon J; O'Dorisio TM; Howe JR
Surgery; 2017 Jan; 161(1):272-279. PubMed ID: 27863780
[TBL] [Abstract][Full Text] [Related]
24. DNA methyltransferases 1, 3a, and 3b overexpression and clinical significance in gastroenteropancreatic neuroendocrine tumors.
Rahman MM; Qian ZR; Wang EL; Yoshimoto K; Nakasono M; Sultana R; Yoshida T; Hayashi T; Haba R; Ishida M; Okabe H; Sano T
Hum Pathol; 2010 Aug; 41(8):1069-78. PubMed ID: 20381114
[TBL] [Abstract][Full Text] [Related]
25. Liver transplantation for gastroenteropancreatic neuroendocrine cancers: Defining selection criteria to improve survival.
van Vilsteren FG; Baskin-Bey ES; Nagorney DM; Sanderson SO; Kremers WK; Rosen CB; Gores GJ; Hobday TJ
Liver Transpl; 2006 Mar; 12(3):448-56. PubMed ID: 16498656
[TBL] [Abstract][Full Text] [Related]
26. Loss of expression and prognosis value of alpha-internexin in gastroenteropancreatic neuroendocrine neoplasm.
Wang Y; Chen Y; Li X; Hu W; Zhang Y; Chen L; Chen M; Chen J
BMC Cancer; 2018 Jun; 18(1):691. PubMed ID: 29940892
[TBL] [Abstract][Full Text] [Related]
27. Principal component analysis, hierarchical clustering, and decision tree assessment of plasma mRNA and hormone levels as an early detection strategy for small intestinal neuroendocrine (carcinoid) tumors.
Modlin IM; Gustafsson BI; Drozdov I; Nadler B; Pfragner R; Kidd M
Ann Surg Oncol; 2009 Feb; 16(2):487-98. PubMed ID: 19050963
[TBL] [Abstract][Full Text] [Related]
28. Renal cell carcinoma: relevance of angiogenetic factors.
Wechsel HW; Bichler KH; Feil G; Loeser W; Lahme S; Petri E
Anticancer Res; 1999; 19(2C):1537-40. PubMed ID: 10365140
[TBL] [Abstract][Full Text] [Related]
29. Evaluating the efficacy of tumor markers CA 19-9 and CEA to predict operability and survival in pancreatic malignancies.
Mehta J; Prabhu R; Eshpuniyani P; Kantharia C; Supe A
Trop Gastroenterol; 2010; 31(3):190-4. PubMed ID: 21560524
[TBL] [Abstract][Full Text] [Related]
30. Circulating biomarkers in neuroendocrine tumors of the enteropancreatic tract: application to diagnosis, monitoring disease, and as prognostic indicators.
Ardill JE; O'Dorisio TM
Endocrinol Metab Clin North Am; 2010 Dec; 39(4):777-90. PubMed ID: 21095544
[TBL] [Abstract][Full Text] [Related]
31. Intervention in gastro-enteropancreatic neuroendocrine tumours.
Baudin E; Planchard D; Scoazec JY; Guigay J; Dromain C; Hadoux J; Debaere T; Elias D; Ducreux M
Best Pract Res Clin Gastroenterol; 2012 Dec; 26(6):855-65. PubMed ID: 23582924
[TBL] [Abstract][Full Text] [Related]
32. Cytokines in pancreatic carcinoma: correlation with phenotypic characteristics and prognosis.
Ebrahimi B; Tucker SL; Li D; Abbruzzese JL; Kurzrock R
Cancer; 2004 Dec; 101(12):2727-36. PubMed ID: 15526319
[TBL] [Abstract][Full Text] [Related]
33. [Clinicopathological characterization of gastro-entero- pancreatic neuroendocrine tumors].
Borka K
Magy Onkol; 2018 Jul; 62(2):90-97. PubMed ID: 30027936
[TBL] [Abstract][Full Text] [Related]
34. Serotonin levels and 1-year mortality in patients with neuroendocrine tumors: a systematic review and meta-analysis.
Joish VN; Shah S; Tierce JC; Patel D; McKee C; Lapuerta P; Zacks J
Future Oncol; 2019 Apr; 15(12):1397-1406. PubMed ID: 30734573
[No Abstract] [Full Text] [Related]
35. Cyclooxygenase-2 expression in gastroenteropancreatic neuroendocrine tumors.
Ince AT; Ovünç O; Celikel CA; Göksel S; Tosun S; Peker O
Hepatogastroenterology; 2007 Jun; 54(76):1125-9. PubMed ID: 17629053
[TBL] [Abstract][Full Text] [Related]
36. Circulating angiogenic factors during periovulation and the luteal phase of normal menstrual cycles.
Malamitsi-Puchner A; Sarandakou A; Tziotis J; Stavreus-Evers A; Tzonou A; Landgren BM
Fertil Steril; 2004 May; 81(5):1322-7. PubMed ID: 15136097
[TBL] [Abstract][Full Text] [Related]
37. Discussion.
Surgery; 2016 Jan; 159(1):347. PubMed ID: 26456129
[No Abstract] [Full Text] [Related]
38. The uncovering and characterization of a CCKoma syndrome in enteropancreatic neuroendocrine tumor patients.
Rehfeld JF; Federspiel B; Agersnap M; Knigge U; Bardram L
Scand J Gastroenterol; 2016 Oct; 51(10):1172-8. PubMed ID: 27191542
[TBL] [Abstract][Full Text] [Related]
39. Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors.
Dromain C; Pavel ME; Ruszniewski P; Langley A; Massien C; Baudin E; Caplin ME;
BMC Cancer; 2019 Jan; 19(1):66. PubMed ID: 30642293
[TBL] [Abstract][Full Text] [Related]
40. Exocrine-endocrine pancreatic cancer and alpha-fetoprotein.
Brandi G; Nobili E; Capizzi E; Corti B; Di Cicilia R; Di Marco M; Biasco G
Pancreas; 2008 Aug; 37(2):223-5. PubMed ID: 18665089
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
